Anti-inflammatory Adjuvants in Resuscitation Fluids Improves Survival in Experimental Hemorrhage (93.15)

Weihong Dong,Bolin Cai,Geber Pena,Vadim Pisarenko,Marlon Lee,Laura Ramos,Edwin Deitch,Luis Ulloa
DOI: https://doi.org/10.4049/jimmunol.182.supp.93.15
2009-04-01
The Journal of Immunology
Abstract:Abstract Conventional resuscitation fluids reestablish tissue perfusion, but they fail to prevent lethal inflammatory responses. We reasoned that ethyl pyruvate (EP) can provide a therapeutic anti-inflammatory potential to improve survival during resuscitation. Survival, organ damage, inflammatory responses and characteristic pathways were analyzed after resuscitation of hemorrhagic rodents and swine. All control rodents and swine without resuscitation died within the first 6 hrs after hemorrhage. Resuscitation with Hextend reestablished arterial blood pressure and tissue perfusion, yet 90% of the animals died within 6 hrs after hemorrhage. All the animals treated with 50 mM EP survived hemorrhage. EP prevented systemic inflammation and improved survival in a concentration dependent manner. Unlike Hextend, resuscitation with EP ablated TNF and HMGB1 production, preserved the intestinal epithelium, and prevented bacterial endotoxin in the serum. From a molecular perspective, EP inhibited NF-kB and PARP activation without affecting IKBa activation in major organs and culture of macrophages. USAMRMC#05308004, AHA06352230N, NIH-GM084125.
immunology
What problem does this paper attempt to address?